Mirum reports $76M total rev in 2022; LIVMARLI net sales $74M; CFO Clements to step down

Mirum Pharmaceuticals, Inc.

2022-FY EPS reported -$4.02 revenue$77,062,000

Total revenue $76M, LIVMARLI net product sales $74M for full year 2022 (preliminary unaudited).
Q4 2022 product sales $27M including $5M international partner orders.
CFO Ian Clements to step down effective May 15, 2023; will serve as consultant for 12 months.
sNDA for LIVMARLI in PFIC on track for Q1 2023; multiple pipeline catalysts in 2023.
Cash and investments ~$252M as of Dec 31, 2022.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ian Clements

Chief Financial Officer

MIRM · Mirum Pharmaceuticals, Inc.

Effective: 2023-05-15
Filed: January 9, 2023, 6:59 PM ET

Dr. Clements will resign as Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported 2022 results: revenue $76 million total revenue.

Period: 2022
Revenue: $76 million total revenue
Result: preliminary results

Exact text from the filing

$76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported Fourth quarter 2022 results: revenue $27 million estimated product sales.

Period: Fourth quarter 2022
Revenue: $27 million estimated product sales
Result: preliminary results

Exact text from the filing

Fourth quarter 2022 estimated product sales of $27 million includes an estimated $5 million of international sales through partner market supply orders, including inventory;

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ian Clements departed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..

Action: resign
Role: Chief Financial Officer

Exact text from the filing

Dr. Clements will resign as Chief Financial Officer of the Company.

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.